

ABSTRACT OF THE DISCLOSURE

The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are pharmacological preparations to be used to increase the levels of radiosensitizing compounds such as TNF- α , or radioprotective compounds such as MnSOD, in specified tissues or tumors of a subject.

10